Y-mAbs Therapeutics (YMAB) Misses Q2 EPS by 9c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Y-mAbs Therapeutics (YMAB) PT Lowered to $25 at BMO Capital
August 12, 2024 4:08 PM EDTBMO Capital analyst Etzer Darout lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $25.00 (from $26.00) while maintaining a Outperform rating.
The analyst comments "YMAB reported 2Q24 total revenues of $22.8M, a touch below FactSet consensus (-0.9%) but ahead of our estimate (+3.6%).... More
